<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01589315</url>
  </required_header>
  <id_info>
    <org_study_id>FEAST for depression</org_study_id>
    <nct_id>NCT01589315</nct_id>
  </id_info>
  <brief_title>Focal Electroconvulsive Therapy for Depression</brief_title>
  <acronym>FEAST</acronym>
  <official_title>Focal Electrical Administered Seizure Therapy (FEAST) for Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot, open label investigation evaluates the safety and efficacy of a new form of&#xD;
      electroconvulsive therapy (ECT). Both the efficacy and adverse cognitive effects of ECT are&#xD;
      highly contingent on the intracerebral current paths and current density of the ECT stimulus.&#xD;
      However, the impedance of the skull and individual differences in skull anatomy severely&#xD;
      limit the spatial targeting of stimulation, and create marked individual differences in&#xD;
      intracerebral current density. To address these problems, the investigators are exploring&#xD;
      various means of overcoming this limitation.&#xD;
&#xD;
      An approach is to modify the electrical stimulus to induce focal seizures. The most common&#xD;
      methods of ECT administration in the US use a bidirectional, constant current, brief pulse,&#xD;
      with large (approximately 3 sq. in. surface area) and identically sized and shaped&#xD;
      electrodes. In contrast, in this protocol the investigators have coupled unidirectional&#xD;
      current flow with an electrode geometry involving a small and large electrode that differ by&#xD;
      more than 3:1 in surface area.&#xD;
&#xD;
      Unidirectional currents were widely used in ECT during the, 1940's and continue to be used in&#xD;
      European and American devices today. Transcranial electrical stimulation can be made focal by&#xD;
      stimulating with an anode-cathode arrangement, with the electrodes differing in surface area.&#xD;
      The investigators have shown in nonhuman primates the capacity to produce focal frontal&#xD;
      seizure induction under conditions when a unidirectional current flows from a small anterior&#xD;
      anode (placed on the forehead over the nasion) to a large posterior cathode just anterior to&#xD;
      the motor strip. Furthermore, the investigators expect that some, if not all, of these&#xD;
      seizures do not result in motor convulsions.&#xD;
&#xD;
      Thirty outpatients referred for ECT will participate. Relative to concurrent reference data&#xD;
      from our ongoing ECT protocols, the investigators hypothesize that acute and subacute adverse&#xD;
      cognitive effects of FEAST will be substantially less than those in patients receiving&#xD;
      state-of-the art ECT, but with a traditional bidirectional, nonfocal stimulus. The&#xD;
      investigators also hypothesize that the majority of patients will remit with FEAST. Thus, by&#xD;
      improving the efficiency of the ECT stimulus with the switch to unidirectional current and&#xD;
      the use of a new electrode geometry, the investigators expect to be able to induce focal&#xD;
      seizures. The investigators hypothesize that this pilot study will provide evidence that this&#xD;
      treatment is superior to traditional ECT in having lower dosing requirements and a superior&#xD;
      side effect profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will provide preliminary evaluation of the following:&#xD;
&#xD;
        1. Determination of whether focal seizures can be induced with the FEAST methodology&#xD;
           (unidirectional stimulation, small anterior and large posterior electrode).&#xD;
&#xD;
             1. Focality will be assessed by the occurrence of non-motor seizures.&#xD;
&#xD;
             2. Electroencephalographic evidence of pronounced asymmetry in frontal leads.&#xD;
&#xD;
        2. Determination of whether the FEAST methodology results in reduced seizure threshold.&#xD;
&#xD;
           a. Seizure threshold will be quantified at the start of the treatment course using the&#xD;
           standard method of limits titration procedure and compared to threshold determinations&#xD;
           in matched patients who were treated with conventional ECT methods.&#xD;
&#xD;
        3. Characterization of dynamic impedance using the FEAST methodology.&#xD;
&#xD;
           a. Dynamic impedance during the passage of the electrical stimulus will be quantified&#xD;
           during each administration and compared to the values obtained in matched patients who&#xD;
           were treated with conventional ECT methods.&#xD;
&#xD;
        4. Characterization of the efficacy of the FEAST methods and the safety of the treatment.&#xD;
&#xD;
             1. The primary efficacy measure will be the 24-item Hamilton Rating Scale for&#xD;
                Depression. The changes in these scores from before to immediately following the&#xD;
                treatment course will be compared in patients treated with the FEAST methodology&#xD;
                and matched patients who were treated with conventional ECT methods.&#xD;
&#xD;
             2. Acute, subacute, and long-term cognitive side effects following FEAST will be&#xD;
                assessed with comprehensive neuropsychological batteries. The primary acute&#xD;
                measures will include the time to return of orientation following seizure induction&#xD;
                and retrograde amnesia for words and shapes. The primary subacute measures will&#xD;
                include assessments of anterograde amnesia (forgetting over a delay) for a verbal&#xD;
                list and for reproduction of a complex figure, as well as retrograde amnesia for&#xD;
                autobiographical information. The primary long-term measure will be retrograde&#xD;
                amnesia for autobiographical information, assessed 6-months following the FEAST&#xD;
                course. The neuropsychological measures will be compared in the patients treated&#xD;
                with the FEAST methodology and matched patients who were treated with conventional&#xD;
                ECT methods, as well as in healthy participants who receive were administered the&#xD;
                neuropsychological battery at the same intervals as the FEAST patients, but without&#xD;
                Intervention.&#xD;
&#xD;
             3. Safety will also be determined by examining the number and frequency of serious&#xD;
                adverse advents and adverse events, as well as scores on the Columbia University&#xD;
                ECT Side Effect Scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item.</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>The number of treatment sessions is not fixed and could extend up to 12 provided that patients show continued improvement and tolerate the treatment. With 3 FEAST sessions per week, the course may take up to 12 weeks to be completed.&#xD;
The Hamilton Rating Scale for Depression is a widely used clinician administered rating.Scores range from (Min) 0 to (Max) 52. Higher score means worse depression. The definition of remission was a Ham Depression Score (24 item) of &lt; or equal to 10.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>FEAST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active right unilateral focal ECT</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>focal ECT</intervention_name>
    <description>FEAST, ECT, unidirectional stimulation</description>
    <arm_group_label>FEAST</arm_group_label>
    <other_name>FEAST, ultra-brief unidirectional right ECT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 90 years (inclusive)&#xD;
&#xD;
          -  Diagnosis of major depressive disorder&#xD;
&#xD;
          -  Pretreatment HRSD score â‰¥ 18&#xD;
&#xD;
          -  ECT indicated&#xD;
&#xD;
          -  Willing and capable of providing informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of schizophrenia,&#xD;
&#xD;
          -  schizoaffective disorder,&#xD;
&#xD;
          -  other functional psychosis, or&#xD;
&#xD;
          -  rapid cycling bipolar disorder&#xD;
&#xD;
          -  History of neurological illness or insult other than conditions associated with&#xD;
             psychotropic exposure (e.g., tardive dyskinesia)&#xD;
&#xD;
          -  Alcohol or substance abuse or dependence in the past year (RDC)&#xD;
&#xD;
          -  Secondary diagnosis of a delirium, dementia, or amnestic disorder (DSM-IV), pregnancy,&#xD;
             or epilepsy&#xD;
&#xD;
          -  Requires especially rapid antidepressant response due to suicidality, psychosis,&#xD;
             inanition, psychosocial obligations, etc.&#xD;
&#xD;
          -  Unable to tolerate psychotropic washout and no psychotropic medication during the ECT&#xD;
             trial, other than lorazepam (up to 3 mg/d PRN)&#xD;
&#xD;
          -  ECT in the past six months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziad Nahas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sackeim HA. Memory and ECT: from polarization to reconciliation. J ECT. 2000 Jun;16(2):87-96. Review.</citation>
    <PMID>10868319</PMID>
  </reference>
  <reference>
    <citation>HOVORKA EJ, SCHUMSKY DA, WORK MS. Electroconvulsive thresholds as related to stimulus parameters of unidirectional ECS. J Comp Physiol Psychol. 1960 Aug;53:412-4.</citation>
    <PMID>14403427</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <results_first_submitted>May 29, 2019</results_first_submitted>
  <results_first_submitted_qc>August 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>August 16, 2019</last_update_submitted>
  <last_update_submitted_qc>August 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECT</keyword>
  <keyword>FEAST</keyword>
  <keyword>brain stimulation</keyword>
  <keyword>depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>We planned to enroll up to 20 but only enrolled 17 due to time and budget issues.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FEAST</title>
          <description>Active right unilateral focal ECT&#xD;
focal ECT: FEAST, ECT, unidirectional stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FEAST</title>
          <description>Active right unilateral focal ECT&#xD;
focal ECT: FEAST, ECT, unidirectional stimulation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HRSD24</title>
          <description>The Hamilton Rating Scale for Depression is a widely used clinician administered rating. We used the 24 -item version. Scores can range from (Min) 0 to (Max) 52. Higher score means worse depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item.</title>
        <description>The number of treatment sessions is not fixed and could extend up to 12 provided that patients show continued improvement and tolerate the treatment. With 3 FEAST sessions per week, the course may take up to 12 weeks to be completed.&#xD;
The Hamilton Rating Scale for Depression is a widely used clinician administered rating.Scores range from (Min) 0 to (Max) 52. Higher score means worse depression. The definition of remission was a Ham Depression Score (24 item) of &lt; or equal to 10.</description>
        <time_frame>up to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FEAST</title>
            <description>Active right unilateral focal ECT&#xD;
focal ECT: FEAST, ECT, unidirectional stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Based on HDRS, Hamilton Depression Rating Scale, 24 Item.</title>
          <description>The number of treatment sessions is not fixed and could extend up to 12 provided that patients show continued improvement and tolerate the treatment. With 3 FEAST sessions per week, the course may take up to 12 weeks to be completed.&#xD;
The Hamilton Rating Scale for Depression is a widely used clinician administered rating.Scores range from (Min) 0 to (Max) 52. Higher score means worse depression. The definition of remission was a Ham Depression Score (24 item) of &lt; or equal to 10.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>FEAST</title>
          <description>Active right unilateral focal ECT&#xD;
focal ECT: FEAST, ECT, unidirectional stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>first degree burn at electrode</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mark S. George, MD</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>1843876 5142</phone>
      <email>georgem@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

